Abstract
YM872 {[2,3-dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl]-acetic acid monohydrate}, a selective, potent and highly water-soluble competitive α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist, was investigated for its neuroprotective effect against focal cerebral ischemia in halothane-anesthetized cats. Cats were subjected to permanent occlusion of the left middle cerebral artery for 6 h, then sacrificed and examined histologically. The electroencephalogram and cerebral blood flow were monitored. Intravenous infusion of YM872 starting 10 min after the onset of ischemia at a rate of 2 mg/kg/h for 6 h markedly reduced the volume of ischemic damage by 61% (from 2604 ± 202 mm3 of the cerebral hemisphere in saline-treated cats to 1025 ± 277 mm3 in YM872-treated cats; P < .01), as assessed in 12 stereotaxically determined coronal sections. No significant differences were observed between YM872- and saline-treated cats concerning physiological variables including brain temperature. No precipitation of YM872 in the kidney was seen in any YM872-treated animal. The present data further support the notion that the AMPA receptor plays an important role in the progression of focal ischemic damage in a gyrencephalic model. This evidence for the neuroprotective efficacy of YM872 suggests its therapeutic potential in the treatment of acute stroke in humans.
Footnotes
-
Send reprint requests to: Masayasu Takahashi, M.S., Neuroscience Research, Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka, Tsukuba, Ibaraki 305, Japan.
- Abbreviations:
- AMPA
- α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid
- CBF
- cerebral blood flow
- CGS19755
- cis-4-phosphonomethyl-2-piperidine carboxylic acid
- CSF
- cerebrospinal fluid
- d-CPP-ene
- d-(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxilic acid
- EEG
- electroencephalogram
- HPLC
- high-performance liquid chromatography
- LDF
- laser Doppler flowmetry
- LY-293558
- (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl] decahydroisoquinoline-3-carboxylic acid
- MCA
- middle cerebral artery
- NBQX
- 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo (F) quinoxaline
- NMDA
- N-methyl-d-aspartate
- VSCC
- voltage-sensitive calcium channel
- YM90K
- [6-(1H-imidazol-1-yl)-7-nitro-2, 3(1H, 4H)-quinoxalinedione monohydrochloride
- MABP
- mean arterial blood pressure
- ANOVA
- analysis of variance
- Received February 12, 1997.
- Accepted October 27, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|